There are times when you hold new technology in your hands and realize that you are looking at something special, something that will, to use an oft-cited cliché, be a “game-changer.” A lot of times this realization happens in conjunction with con- sumer electronics; I remember the first time I held a compact disc and thought what a leap it represented compared to current technol-
ogy; for others it might have been the first time you held an iPod or
a smart phone; you just know you have something special in your
hands – and it’s exciting. I am reminded of this because the FDA re-
cently approved MannKind’s inhalable insulin product, Afrezza.
Inhalable insulin, by itself is not a new idea, or even a new product. In 2007, Pfizer stopped selling its inhaled insulin Exubera after
it failed to gain ground on the market. Other companies have also
tried to market inhaled insulin but have ended their development
So what makes Afrezza so unique? It has to be its delivery system.
Back in 2010, MannKind won two ISPE Facility of the Year Awards
(FOYA), for Equipment Innovation and Process Innovation. I recall being at INTERPHEX that year and visiting MannKind’s FOYA booth and
being shown the Afrezza delivery device. It was small, it was compact, it fit in the palm of your hand, it could easily go in your pocket
or purse it was, what I thought, a game-changer.
The road to get Afrezza approved has not been an easy one. The
FDA had asked MannKind for numerous additional clinical trials along
the way to approval, and the product as approved does carry an FDA
“black box” warning – the strongest warning issued by the FDA for
But its approved and now on the market – and I predict it will be a
It's All In The Delivery
Have a comment or question about Pharmaceutical Processing?
My E-mail is: firstname.lastname@example.org
Inhalable insulin is not a new product. In
2007, Pfizer stopped selling Exubera after it
failed to gain market share. Other companies
have also tried to market inhaled insulin but
have ended their development programs.
■ Michael Auerbach, Editor in Chief
ASSOCIATE PUBLISHER BILL KOENEN
AL, CT, DC, FL, GA, IA, IL, IN 199 EAST BADGER ROAD, SUITE 201
KY, MA, MI, MO, NH, NJ, NV Madison, WI 52713
NY, OH, PA, SC, TN, VT, WI Tel: 973-920-7793
NE W BRUNSWICK, ONTARIO, Fax: 973-607-5682
QUEBEC, CANADA email@example.com
SALES DAVID OLESTON
AR, AZ, BC, CA, CO 199 EAST BADGER ROAD, SUITE 201
DE, ID, SK, LA, MD Madison, WI 52713
ME, MN, MS, MT Tel: 973-920-7706
NC, NE, OK, OR Fax: 973-607-5516
SD, TX, UT, VA, WA firstname.lastname@example.org
ADMINISTRATIVE ASSISTANT KATIE LOZANO
WHITE PAPERS & WEBCASTS 973-920-7796
REPRINTS BRAD HAIRHOGER
SUBSCRIPTION RELATED Contact ABM@omeda.com or
MATTERS call 847-559-7560 for assistance.
LIST RENTALS Infogroup Targeting Solutions
Senior Account Manager
Bart Piccirillo; 402-836-6283;
Senior Account Manager
Michael Costantino; 402-863-6266
EDITORIAL ADVISORY BOARD
Michael J. Beier,
Senior Vice President of Operations
TITAN PHARMACEUTICALS, INC.
Dr. James V. Blackwell, PhD, Consultant
BIOPROCESS TECHNOLOGY CONSULTANTS, INC.
Ronald C. Branning,
Vice President Global Quality
Robert F. Dream, Vice President
H.D.R. COMPANY LTD.
Johanna Carmel Egan,
VGP Project Management
Girish Malhotra, President
Allan F. Pfitzenmaier, President
VECTECH PHARMA CONSULTANTS INC.
Susan Polizzotto, Manager,
R&D QA GMP Compliance
US SANOFI PASTEUR
Carlos Villalobos, Sr. Dir. Global Engineering
Richard G. Whitfield, Senior Director
Patrick Wong, Director of Global Engineering
BRISTOL-MYERS SQUIBB (BMS)